BATF3 and neoplasm: Using these mice as tumor-bearing hosts, we observed that therapeutic antitumor immunity elicited by DCIL-15-based DNA vaccines required host Batf3+ DC subsets in both the GL26 and 4T1.2-Neu models (Fig. 2A and B).